Updates are available Correction dated 2023-09-27
Click to view Correction: https://doi.org/10.1038/s41408-023-00923-6
-
Authors
Martin, Thomas http://orcid.org/0000-0002-9133-9813
Dimopoulos, Meletios-Athanasios http://orcid.org/0000-0001-8990-3254
Mikhael, Joseph http://orcid.org/0000-0001-9670-2864
Yong, Kwee http://orcid.org/0000-0002-6487-276X
Capra, Marcelo
Facon, Thierry
Hajek, Roman http://orcid.org/0000-0001-6955-6267
Špička, Ivan
Baker, Ross
Kim, Kihyun
Martinez, Gracia
Min, Chang-Ki
Pour, Ludek
Leleu, Xavier http://orcid.org/0000-0002-9822-4170
Oriol, Albert http://orcid.org/0000-0001-6804-2221
Koh, Youngil
Suzuki, Kenshi
Casca, France
Macé, Sandrine
Risse, Marie-Laure
Moreau, Philippe
-
Funding
Funding for this research was provided by:
Sanofi (N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A., N.A.)
- License Information
-
More Information
Article History
Received: 25 October 2022
Revised: 24 January 2023
Accepted: 2 February 2023
First Online: 9 May 2023
Change Date: 27 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-023-00923-6
Competing interests
: TM: research funding (to institution) from Sanofi; participation on a steering committee for Sanofi. M-AD: participation in advisory boards for Amgen, BeiGene, Bristol Myers Squibb, Janssen, and Takeda. JM: honoraria from Amgen, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda. KY: research funding from Bristol Myers Squibb, Janssen, and Sanofi; honoraria and travel support from Amgen, Sanofi, and Takeda; participation on an advisory board or steering committee for Janssen and Sanofi. MC: participation in speaker’s bureau for Amgen, Janssen, and Sanofi. TF: participation on a data safety monitoring board or advisory board for Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Oncopeptides, Roche, and Sanofi; speakers’ bureau for Bristol Myers Squibb and Janssen. RH: honoraria and consulting/advisory role for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, PharmaMar, and Takeda; research funding (to institution) from Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, and Takeda; participation on a data safety monitoring board or advisory board for Amgen, Bristol Myers Squibb, GSK, Janssen, Oncopeptides, Sanofi, and Takeda; support for attending meetings and/or travel from Amgen, Celgene, Janssen, and Takeda. IŠ: research funding, honoraria, and participation on a data safety monitoring board or advisory board for Amgen, Bristol Myers Squibb, Celgene, Janssen-Cilag, Novartis, PharmaMar, Sanofi, and Takeda. RB: research funding from AbbVie, Acerta Pharma, Alexion, Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Janssen-Cilag, MorphoSys, Pfizer, Rigel Pharmaceuticals, Roche, Sanofi, and Takeda; honoraria from Bayer; consulting or advisory role for Janssen-Cilag and Roche; speaker’s bureau for Bayer. KK: research funding from Bristol Myers Squibb and Janssen. GM: nothing to disclose. C-KM: nothing to disclose. LP: nothing to disclose. XL: nothing to disclose. AO: honoraria from Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, and Sanofi; participation on a data safety monitoring board or advisory board for Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, and Sanofi. YK: nothing to disclose. KS: honoraria from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, Ono Pharmaceutical, Sanofi, and Takeda. FC: employed by Ividata Life Science, contracted by Sanofi. SM: employed by Sanofi; may hold stock and/or stock options. M-LR: employed by Sanofi; may hold stock and/or stock options. PM: honoraria and consulting/advisory role for AbbVie, Amgen, Celgene, Janssen, Oncopeptides, Roche, and Sanofi.
